On November 10, 2026, Pacific Biosciences of California, Inc. (PacBio), developer of the world’s most advanced sequencing technologies, entered into a sales agreement with Allen & Company LLC to offer up to $100 million of its common stock through an at-the-market program. Under the terms of the agreement, PacBio may offer and sell shares of its common stock having an aggregate offering price of up to $100 million from time to time through or to Allen & Company LLC, acting as PacBio’s sales agent or principal. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.

PacBio intends to use the proceeds from this offering, together with existing cash, cash equivalents, and investments, for research and development and working capital and general corporate purposes.

The Wilson Sonsini team that advised PacBio on the transaction included Andrew Hoffman, Zachary Myers, Annie Giomi, James Keegan, and Mounika Yepuri.

For more information, please see PacBio’s prospectus supplement.